ICU Medical (ICUI) Set to Announce Quarterly Earnings on Thursday

Share on StockTwits

ICU Medical (NASDAQ:ICUI) will be announcing its earnings results after the market closes on Thursday, November 8th. Analysts expect the company to announce earnings of $1.26 per share for the quarter. ICU Medical has set its FY18 guidance at $8.30-8.70 EPS.

ICU Medical (NASDAQ:ICUI) last posted its earnings results on Thursday, August 9th. The medical instruments supplier reported $2.66 earnings per share for the quarter, topping the consensus estimate of $1.82 by $0.84. The firm had revenue of $360.46 million during the quarter, compared to the consensus estimate of $337.60 million. ICU Medical had a net margin of 5.93% and a return on equity of 12.78%. The company’s revenue was up 8.7% on a year-over-year basis. During the same quarter last year, the company earned $0.76 earnings per share. On average, analysts expect ICU Medical to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.

ICUI opened at $254.73 on Thursday. The stock has a market capitalization of $5.19 billion, a PE ratio of 46.63 and a beta of 0.41. ICU Medical has a twelve month low of $180.45 and a twelve month high of $321.70.

In other news, VP Virginia Ruth Sanzone sold 787 shares of the firm’s stock in a transaction that occurred on Tuesday, August 28th. The shares were sold at an average price of $303.12, for a total value of $238,555.44. Following the completion of the transaction, the vice president now directly owns 1,367 shares in the company, valued at $414,365.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Thomas D. Mccall sold 11,133 shares of the firm’s stock in a transaction that occurred on Friday, August 24th. The shares were sold at an average price of $302.56, for a total transaction of $3,368,400.48. Following the completion of the transaction, the vice president now owns 3,018 shares of the company’s stock, valued at $913,126.08. The disclosure for this sale can be found here. Insiders sold 711,920 shares of company stock valued at $202,651,956 in the last quarter. Corporate insiders own 12.50% of the company’s stock.

Several equities analysts have recently weighed in on ICUI shares. Zacks Investment Research upgraded shares of ICU Medical from a “hold” rating to a “strong-buy” rating and set a $337.00 target price for the company in a research note on Wednesday, August 15th. ValuEngine downgraded shares of ICU Medical from a “buy” rating to a “hold” rating in a research note on Tuesday, September 18th. BidaskClub upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Friday, September 28th. Finally, TheStreet upgraded shares of ICU Medical from a “c+” rating to a “b+” rating in a research note on Monday, August 20th.

About ICU Medical

ICU Medical, Inc develops, manufactures, and sells medical devices used in vascular therapy, critical care, and oncology applications worldwide. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patient's vein.

Featured Article: Why is insider trading harmful?

Earnings History for ICU Medical (NASDAQ:ICUI)

Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply